| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Cardiac muscle myosin 4.4 μM (IC50) Skeletal muscle myosin 9.1 μM (IC50) Smooth muscle myosin II >100 μM (IC50)
JB061 targets nonmuscle myosin II, with selective inhibitory activity against cardiac muscle myosin (IC50 = 4.4 μM), skeletal muscle myosin (IC50 = 9.1 μM), and smooth muscle myosin II (IC50 > 100 μM). It exhibits poor inhibition of ATPase activity with an IC50 exceeding 200 μM. The compound shows selectivity for different myosin isoforms, with cardiac myosin being the most sensitive target. |
|---|---|
| ln Vitro |
In Cos-7 cells, JB061 (compound 6a) (40 μM; 24 h) suppresses cytokinesis [1].
In vitro, JB061 demonstrates cytotoxic effects on COS-7 cells with an IC50 of 39 μM. It shows limited efficacy in reducing ATPase activity (IC50 > 200 μM). The compound exhibits selective inhibitory activity with IC50 values of 4.4 μM for cardiac muscle myosin, 9.1 μM for skeletal muscle myosin, and greater than 100 μM for smooth muscle myosin II. |
| ln Vivo |
Specific in vivo activity data for JB061 are not detailed in available sources. As a myosin inhibitor with demonstrated in vitro cytotoxicity, it may have potential for in vivo studies in models where myosin function is implicated. Further investigation would be required to characterize its in vivo efficacy and pharmacokinetic properties.
|
| Enzyme Assay |
Non-cellular assays for JB061 typically involve measuring its inhibitory activity against purified myosin isoforms. The compound is incubated with the enzyme and ATP, and the inhibition of ATPase activity is quantified to determine IC50 values. These assays provide direct evidence of the compound's potency and selectivity for different myosin isoforms.
|
| Cell Assay |
In vitro cellular assays are performed using cell lines such as COS-7 to assess the cytotoxic effects of JB061. Cells are treated with varying concentrations of the compound, and cell viability is measured using standard assays such as MTT or CellTiter-Glo to determine IC50 values for cytotoxicity.
|
| Animal Protocol |
In vivo animal experiments for JB061 are not detailed in available sources. For myosin inhibitors, such studies would typically involve administering the compound to appropriate animal models to evaluate its effects on muscle function, cytotoxicity, and pharmacokinetic properties.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for JB061 are not detailed in available sources. The compound has a molecular weight of 323.41 and a molecular formula of C18H21NO5. It is soluble in DMSO (4 mg/mL, 12.37 mM) and should be stored as a powder at -20°C for up to 3 years.
|
| Toxicity/Toxicokinetics |
Toxicological data for JB061 are limited. The compound shows cytotoxicity against COS-7 cells with an IC50 of 39 μM. As a research compound, its comprehensive safety profile has not been extensively characterized. It is intended for research use only and not for human consumption.
|
| References | |
| Additional Infomation |
JB061 has a purity of 99.76% and is supplied as a research compound. It is categorized as a myosin inhibitor and is used in cytoskeletal signaling pathway research. The compound is available in various package sizes and is intended for laboratory use only. No clinical trial or regulatory approval information is available.
|
| Molecular Formula |
C19H17NO4
|
|---|---|
| Molecular Weight |
323.34
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~25 mg/mL (~77.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0927 mL | 15.4636 mL | 30.9272 mL | |
| 5 mM | 0.6185 mL | 3.0927 mL | 6.1854 mL | |
| 10 mM | 0.3093 mL | 1.5464 mL | 3.0927 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
